{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.5","upperLimit":"34.0","value":"21.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants in the analysis population who experienced a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 based on BICR evaluation. The percentage of participants who had tumors which were HPV positive and who experienced a CR or PR in the combined Cohorts B2 and B2 was presented for the first course of pembrolizumab treatment per protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab, 10 mg/kg, IV once every 2 weeks or pembrolizumab, 200 mg, IV once every 3 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"OG000","title":"Cohorts B & B2: Head & Neck Cancer HPV-Positive Participants"}],"paramType":"NUMBER","populationDescription":"The population consisted of all Cohort B and Cohort B2 HPV-positive participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression (Up to ~ 35 months) - through FA cutoff date 26 Apr 2016","title":"Overall RECIST 1.1 Response Rate Based on BICR Review, Cohorts B and B2 Human Papilloma Virus (HPV)-Positive Participants","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}